IDEXX Laboratories Inc (IDXX)

166.55
3.63 2.13
NASDAQ : Health Care
Prev Close 170.18
Open 170.56
Day Low/High 166.11 / 171.37
52 Wk Low/High 63.48 / 95.55
Volume 580.53K
Avg Volume 634.90K
Exchange NASDAQ
Shares Outstanding 88.12M
Market Cap 14.68B
EPS 2.50
P/E Ratio 61.71
Div & Yield N.A. (N.A)

Latest News

Idexx Laboratories Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Liberty Interactive

Idexx Laboratories Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Liberty Interactive

The most recent short interest data has been released for the 06/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)

A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)

Growth stock are taking a breather, says Jim Cramer. So here's your game plan for next week.

Analysts' Actions -- Box, Caesar's, Goodyear, Idexx Labs and More

Analysts' Actions -- Box, Caesar's, Goodyear, Idexx Labs and More

Here are Thursday's top research calls, including upgrades for Box and Goodyear, and new coverage of Caesar's Entertainment and Idexx Labs.

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Biogen's new spine disease drug outperformed expectations during its commercial debut.

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

These 'Rocket Stocks' Look Ready for Blastoff

These 'Rocket Stocks' Look Ready for Blastoff

These four stocks are showing short-term gain catalysts and longer-term growth potential.

These 4 'Rocket Stocks' Look Ready for Blastoff

These 4 'Rocket Stocks' Look Ready for Blastoff

These four stocks are showing short-term gain catalysts and longer-term growth potential.

Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update

Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update

Here are the highlights from the final round of our Market Bracket Challenge tournament.

Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update

Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update

Here are the highlights from the fifth round of our tournament, which will end with an epic tech clash between Apple and Facebook.

Snap's Cinderella Story Continues to Unfold as Nike Squeaks By AT&T: An Update From the Challenge

Snap's Cinderella Story Continues to Unfold as Nike Squeaks By AT&T: An Update From the Challenge

It has been a wild ride through two rounds of action.

Snap Pulls Off Miracle, Can the Good Times Continue? An Update From the Challenge

Snap Pulls Off Miracle, Can the Good Times Continue? An Update From the Challenge

It has been a wild ride thus far, and we've only completed one round of action.

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

The top 64 companies taking a trip to TheStreet's 2017 Market Bracket Challenge tournament.

Idexx Laboratories: Why I'm Avoiding This Puppy

Idexx Laboratories: Why I'm Avoiding This Puppy

Households now spend more on their pets than cable TV.

Bonds Call the Tune Today, Not Stocks: Cramer's 'Mad Money' Recap (Thursday 2/9/17)

Bonds Call the Tune Today, Not Stocks: Cramer's 'Mad Money' Recap (Thursday 2/9/17)

When bond yields rise, the economy roars and it's game on for industrials, banks and retailers, says Jim Cramer.

Cramer: Reward vs. Political Risk

Cramer: Reward vs. Political Risk

Trump has made it harder to decide how much volatility you can stand.

Jim Cramer -- Idexx Labs Isn't Done Rallying

Jim Cramer -- Idexx Labs Isn't Done Rallying

Idexx Laboratories beat on earnings per share and revenue expectations, but the trend is still good, Cramer said.

Amazon, Merck, Freshpet: Jim Cramer's Views

Amazon, Merck, Freshpet: Jim Cramer's Views

Cramer shares his views on the pajama traders, and talks turkey about pet stocks.

Jim Cramer's Top Takeaways: VCA, Johnson Controls, Adient

Jim Cramer's Top Takeaways: VCA, Johnson Controls, Adient

Cramer can't understand why shares of Johnson Controls spinoff Adient aren't trading higher.

These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap

These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap

Going into earnings what the market needs now is more negativity, Cramer says.